Sangamo Therapeutics Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Sangamo Biosciences (SGMO) Tops Q3 EPS by 4c, Revs Beat
November 9, 2017 4:26 PM ESTSangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.15), $0.04 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $10.36 million.
GUIDANCE:
Sangamo Biosciences sees FY2017 revenue of $30-40 million, versus the consensus of... More
